GlassScriptPhysician profile
Waseemullah Khan
NPI 1073557864
$22,102.52
in general payments reported to CMS, 2019-2025
92 companies · $2,690 in 2025
The $2,690 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,883 · 2020: $1,896 · 2021: $2,584 · 2022: $4,558 · 2023: $3,338 · 2024: $4,153 · 2025: $2,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,021 · Long Term Medical Supply Or Device Loan: $881 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,020.85 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $279.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $1,854.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,808.47 | 2019-2025 | Piqray, Kisqali |
| Pfizer INC. | $1,475.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,169.07 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $1,125.20 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $962.15 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Amgen INC. | $724.28 | 2019-2025 | Blincyto, Lumakras, Kyprolis |
| Janssen Biotech, INC. | $610.65 | 2019-2025 | Erleada, Imbruvica, Darzalex |
| Celgene Corporation | $556.19 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $538.81 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $519.08 | 2019-2023 | Adcetris, Tukysa, Tivdak |
| Lilly USA, LLC | $508.77 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $490.78 | 2019-2025 | |
| Daiichi Sankyo INC. | $465.65 | 2019-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $449.65 | 2019-2025 | Venclexta, Polivy, Tecentriq |
Show all 91 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waseemullah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.